Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02500628 · ClinicalTrials.gov registry record · Phase 2

Heart Rate Variability in Response to Metformin Challenge

A Phase 2 study of Diabetes Mellitus, Type 2 and Fibromyalgia, sponsored by Woodinville Psychiatric Associates.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
1
Study location

NCT02500628 is a Phase 2 study of Diabetes Mellitus, Type 2 and Fibromyalgia that has completed, run by Woodinville Psychiatric Associates. The registered enrollment target is 61 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02500628, a Phase 2 study of Diabetes Mellitus, Type 2 and Fibromyalgia, has completed, sponsored by Woodinville Psychiatric Associates.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then provide an additional sample 2 hours later.

Interventions

  • DRUG Metformin

Study Locations (1)

Washington

  • Woodinville Psychiatric Associates - Woodinville

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2015-07
Est. Completion 2016-02
Phase Phase 2

What the Registry Record Tells You About NCT02500628

The ClinicalTrials.gov registry entry for NCT02500628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Woodinville Psychiatric Associates, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.

NCT02500628 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT02500628 about?

NCT02500628 is a clinical study titled "Heart Rate Variability in Response to Metformin Challenge". Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will provide a baseline resting ...

What is the current status of trial NCT02500628?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2015-07. Estimated completion is 2016-02.

What conditions does trial NCT02500628 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Fibromyalgia, Movement Disorders, Mitochondrial Diseases.

What interventions are being tested in trial NCT02500628?

The interventions under investigation include: Metformin (DRUG).

Who is sponsoring clinical trial NCT02500628?

This trial is sponsored by Woodinville Psychiatric Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02500628 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.